Advances and Innovations in Multiple Myeloma
Having access to latest innovations in treatment is crucial to achieving optimum outcomes for patients with multiple myeloma (MM). Equally important is providing appropriate and consistent supportive care for management of adverse effects caused by myeloma and/or its treatment. Therefore, health care providers managing the patients with MM, including oncology nurses and advanced practice nurses, need to be aware of new information including best treatment strategy, management of adverse effects and other supportive care measures, and transfer their learnings to patients and other members of the care team.
Often, the best management of any patient with advanced disease is enrollment in a well-designed clinical trial. Clinicians need to be fully apprised of current trials and its benefits to patients to encourage clinical trial participation.
This information was originally presented at the NCCN 2020 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ held on October 8, 2020.
This educational program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Outline currently recommended combination therapies for relapsed/refractory MM.
- Discuss supportive care measures needed for patients with MM as a result of the disease and/or treatment, and outline strategies to manage them.
- Review emerging treatment options and employ effective communication strategies that will help convey the benefits and risks of clinical trial participation to patients.
Patricia Mangan, RN, MSN, APRN-BC
Abramson Cancer Center at the University of Pennsylvania
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Patricia Mangan, RN, MSN, APRN-BC
Amgen Inc.: Product/Speakers Bureau
Bristol-Myers Squibb Company: Product/Speakers Bureau
Celgene Corporation: Product/Speakers Bureau
GlaxoSmithKline: Product/Speakers Bureau
Janssen Pharmaceutica Products, LP: Product/Speakers Bureau
Karyopharm Therapeutics: Product/Speakers Bureau
sanofi-aventis U.S. : Product/Speakers Bureau
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Leadership listed below discloses the following relevant financial relationships:
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer Keller; Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this educational activity for a maximum of 0.75 contact hours.
- 0.75 ANCC contact hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing